Scott Thomas, PhD
Researcher Oncologist
Medicine
School of Medicine

Education & Training

Show all (2) Hide

• PhD Biochemistry, Cell, and Molecular Biology University of California, Davis
• Postdoctoral Studies Graduate Division University of California, San Francisco

Websites

Show all (2) Hide

• Alessa Therapeutics (alessatherapeutics.com)
• Munster Laboratory (munster.ucsf.edu)

Publications (46)

Top publication keywords:
Hydroxamic AcidsKinetochoresEstrogen Receptor ModulatorsEstrogen AntagonistsHistone DeacetylasesBreast NeoplasmsMammary Neoplasms, ExperimentalAntineoplastic Agents, HormonalIndolesEstradiolTamoxifenHistone Deacetylase InhibitorsSelective Estrogen Receptor ModulatorsReceptors, EstrogenEpirubicin

• Prevalence of Futility Protocols for Severely Bleeding Trauma Patients: A Survey from the Association for the Advancement of Blood & Biotherapies (AABB).
  Journal of clinical medicine 2026 Thomas SJ, Waxman DA, Hermelin D, Hartwell E, Gorlin JB, Carayiannis S, Rajbhandary S, Bunch CM, Miller JB, Johnson JL, Lopez-Plaza I, Brancamp RL, Moore EE, Moore HB, Moore PK, Thomas SG, Zimmer DF, …
• First Clinical Description of Coagulation of Whole Blood with Resonant Acoustic Rheometry.
  Diagnostics (Basel, Switzerland) 2025 Bunch CM, Li W, Downey K, Hall TL, Chehimi A, Thomas SJ, Mansoori A, Velasco M, Karam MN, Chen J, Tuttle J, Walsh MR, Thomas SG, Walsh MM, Miller JB, Stegemann JP, Deng CX
• The Effect of Heterogeneous Definitions of Massive Transfusion on Using Blood Component Thresholds to Predict Futility in Severely Bleeding Trauma Patients.
  Journal of clinical medicine 2025 Thomas SJ, Patel VS, Schmitt CP, Zielinski AT, Aboukhaled MN, Steinberg CA, Moore EE, Moore HB, Thomas SG, Waxman DA, Miller JB, Bunch CM, Aboukhaled MW, Thomas EJ, Zackariya SK, Oryakhail H, …
• Characterizing safety, toxicity, and breast cancer risk reduction using a long-term fulvestrant eluting implant.
  Scientific reports 2025 Thomas S, Roche E, Desai P, Pawlowska N, Bauer D, Gingrich D, Hsu E, Deitchman AN, Aweeka F, Munster PN
• Low dose DNA methyltransferase inhibitors potentiate PARP inhibitors in homologous recombination repair deficient tumors.
  Breast cancer research : BCR 2025 Pacaud R, Thomas S, Chaudhuri S, Lazar A, Timmerman LA, Munster PN

Show all (41 more) Hide

• Updated Survival Follow-Up for Phase Ib Trial of the Histone Deacetylase Inhibitor Abexinostat With Pazopanib in Patients With Solid Tumor Malignancies.
  JCO precision oncology 2024 Tsang ES, Aggarwal RR, Bergsland EK, Calabrese S, Rozie A, Chaudhuri S, Dhawan MS, Pawlowska N, Grabowsky J, Thomas S, Munster PN
• Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors With Homologous Recombination-Deficiency Mutations Beyond BRCA1/2.
  JCO precision oncology 2024 Tsang ES, Dhawan MS, Pacaud R, Thomas S, Grabowsky J, Wilch L, Karipineni S, Kelley RK, Ko AH, Collisson E, Chapman JS, Ueda S, Bergsland EK, Munster P
• Corrigendum: Iatrogenic air embolism: pathoanatomy, thromboinflammation, endotheliopathy, and therapies.
  Frontiers in immunology 2024 Marsh PL, Moore EE, Moore HB, Bunch CM, Aboukhaled M, Condon SM, Al-Fadhl MD, Thomas SJ, Larson JR, Bower CW, Miller CB, Pearson ML, Twilling CL, Reser DW, Kim GS, Troyer BM, Yeager D, Thomas SG, …
• A long-term fulvestrant eluting implant is safe, non-toxic, and reduces the risk of breast cancer in in vivo models.
  Research square 2023 Thomas S, Roche E, Desai P, Pawlowska N, Bauer D, Gingrich D, Hsu E, Deitchman AN, Aweeka F, Munster PN
• Iatrogenic air embolism: pathoanatomy, thromboinflammation, endotheliopathy, and therapies.
  Frontiers in immunology 2023 Marsh PL, Moore EE, Moore HB, Bunch CM, Aboukhaled M, Condon SM, Al-Fadhl MD, Thomas SJ, Larson JR, Bower CW, Miller CB, Pearson ML, Twilling CL, Reser DW, Kim GS, Troyer BM, Yeager D, Thomas SG, …
• SHock-INduced Endotheliopathy (SHINE): A mechanistic justification for viscoelastography-guided resuscitation of traumatic and non-traumatic shock.
  Frontiers in physiology 2023 Bunch CM, Chang E, Moore EE, Moore HB, Kwaan HC, Miller JB, Al-Fadhl MD, Thomas AV, Zackariya N, Patel SS, Zackariya S, Haidar S, Patel B, McCurdy MT, Thomas SG, Zimmer D, Fulkerson D, Kim PY, Walsh …
• Reply to Bareille et al. Are Viscoelastometric Assays of Old Generation Ready for Disposal? Comment on "Volod et al. Viscoelastic Hemostatic Assays: A Primer on Legacy and New Generation Devices. J. Clin. Med. 2022, 11, 860".
  Journal of clinical medicine 2023 Volod O, Bunch CM, Miller J, Moore EE, Moore HB, Kwaan HC, Patel SS, Wiarda G, Aboukhaled M, Thomas SG, Fulkerson D, Erdman L, Tincher A, Walsh MM
• Automated digital counselling with social network support as a novel intervention for patients with heart failure: protocol for randomised controlled trial.
  BMJ open 2022 Peiris RG, Ross H, Chan CT, Poon S, Auguste BL, Rac VE, Farkouh M, McDonald M, Kaczorowski J, Code J, Duero Posada J, Ong S, Kobulnik J, Tomlinson G, Huszti E, Arcand J, Thomas SG, Akbari A, Maunder R…
• A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies.
  Cancer research communications 2022 Tsang ES, Aggarwal RR, Dhawan MS, Bergsland EK, Alvarez EA, Calabrese S, Pacaud R, Garcia J, Fattah D, Thomas S, Grabowsky J, Moasser MM, Munster PN
• Viscoelastic Hemostatic Assays: A Primer on Legacy and New Generation Devices.
  Journal of clinical medicine 2022 Volod O, Bunch CM, Zackariya N, Moore EE, Moore HB, Kwaan HC, Neal MD, Al-Fadhl MD, Patel SS, Wiarda G, Al-Fadhl HD, McCoy ML, Thomas AV, Thomas SG, Gillespie L, Khan RZ, Zamlut M, Kamphues P, Fries D…
• Hemorrhagic Resuscitation Guided by Viscoelastography in Far-Forward Combat and Austere Civilian Environments: Goal-Directed Whole-Blood and Blood-Component Therapy Far from the Trauma Center.
  Journal of clinical medicine 2022 Lantry JH, Mason P, Logsdon MG, Bunch CM, Peck EE, Moore EE, Moore HB, Neal MD, Thomas SG, Khan RZ, Gillespie L, Florance C, Korzan J, Preuss FR, Mason D, Saleh T, Marsee MK, Vande Lune S, Ayoub Q, …
• Use of Thromboelastography in the Evaluation and Management of Patients With Traumatic Brain Injury: A Systematic Review and Meta-Analysis.
  Critical care explorations 2021 Cannon JW, Dias JD, Kumar MA, Walsh M, Thomas SG, Cotton BA, Schuster JM, Evans SL, Schreiber MA, Adam EH, Zacharowski K, Hartmann J, Schöchl H, Kaplan LJ
• The effect of marrow secretome and culture environment on the rate of metastatic breast cancer cell migration in two and three dimensions.
  Molecular biology of the cell 2021 Curtis KJ, Mai C, Martin H, Oberman AG, Alderfer L, Romero-Moreno R, Walsh M, Mitros SF, Thomas SG, Dynako JA, Zimmer DI, McNamara LM, Littlepage LE, Niebur GL
• Immunotherapy in breast cancer: A clinician's perspective.
  Journal of the National Cancer Center 2021 Chaudhuri S, Thomas S, Munster P
• Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer.
  Nature communications 2020 Terranova-Barberio M, Pawlowska N, Dhawan M, Moasser M, Chien AJ, Melisko ME, Rugo H, Rahimi R, Deal T, Daud A, Rosenblum MD, Thomas S, Munster PN
• Histone Deacetylase Inhibition with Panobinostat Combined with Intensive Induction Chemotherapy in Older Patients with Acute Myeloid Leukemia: Phase I Study Results.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Wieduwilt MJ, Pawlowska N, Thomas S, Olin R, Logan AC, Damon LE, Martin T, Kang M, Sayre PH, Boyer W, Gaensler KML, Anderson K, Munster PN, Andreadis C
• Local delivery of hormonal therapy with silastic tubing for prevention and treatment of breast cancer.
  Scientific reports 2018 Park J, Thomas S, Zhong AY, Wolfe AR, Krings G, Terranova-Barberio M, Pawlowska N, Benet LZ, Munster PN
• HDAC inhibition potentiates immunotherapy in triple negative breast cancer.
  Oncotarget 2017 Terranova-Barberio M, Thomas S, Ali N, Pawlowska N, Park J, Krings G, Rosenblum MD, Budillon A, Munster PN
• Host histone acetylation unlocks HDAC inhibitor potential.
  Oncotarget 2017 Terranova-Barberio M, Thomas S, Munster PN
• Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors.
  Breast cancer research : BCR 2017 Bartelink IH, Prideaux B, Krings G, Wilmes L, Lee PRE, Bo P, Hann B, Coppé JP, Heditsian D, Swigart-Brown L, Jones EF, Magnitsky S, Keizer RJ, de Vries N, Rosing H, Pawlowska N, Thomas S, Dhawan M, …
• Autologous Fat Grafting as a Novel Antiestrogen Vehicle for the Treatment of Breast Cancer.
  Plastic and reconstructive surgery 2017 Thomas S, Chen S, Sbitany H, Kwon E, Piper M, Park J, Terranova Barberio M, Pawlowska N, Munster PN
• Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2017 Dhawan MS, Bartelink IH, Aggarwal RR, Leng J, Zhang JZ, Pawlowska N, Terranova-Barberio M, Grabowsky JA, Gewitz A, Chien AJ, Moasser M, Kelley RK, Maktabi T, Thomas S, Munster PN
• Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017 Aggarwal R, Thomas S, Pawlowska N, Bartelink I, Grabowsky J, Jahan T, Cripps A, Harb A, Leng J, Reinert A, Mastroserio I, Truong TG, Ryan CJ, Munster PN
• Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors.
  Immunotherapy 2016 Terranova-Barberio M, Thomas S, Munster PN
• A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma.
  Annals of oncology : official journal of the European Society for Medical Oncology 2016 Thomas S, Aggarwal R, Jahan T, Ryan C, Troung T, Cripps AM, Raha P, Thurn KT, Chen S, Grabowsky JA, Park J, Hwang J, Daud A, Munster PN
• Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
  Breast cancer research : BCR 2015 Raha P, Thomas S, Thurn KT, Park J, Munster PN
• Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy.
  Epigenomics 2015 Park J, Thomas S, Munster PN
• Histone deacetylase regulation of ATM-mediated DNA damage signaling.
  Molecular cancer therapeutics 2013 Thurn KT, Thomas S, Raha P, Qureshi I, Munster PN
• Efficacy of histone deacetylase and estrogen receptor inhibition in breast cancer cells due to concerted down regulation of Akt.
  PloS one 2013 Thomas S, Thurn KT, Raha P, Chen S, Munster PN
• Epigenetic modulation: a novel therapeutic target for overcoming hormonal therapy resistance.
  Epigenomics 2011 Raha P, Thomas S, Munster PN
• A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer.
  British journal of cancer 2011 Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, Melisko M, Ismail-Khan R, Rugo H, Moasser M, Minton SE
• Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy.
  Breast cancer research and treatment 2011 Thomas S, Thurn KT, Biçaku E, Marchion DC, Münster PN
• Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer.
  Future oncology (London, England) 2011 Thurn KT, Thomas S, Moore A, Munster PN
• Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker.
  British journal of cancer 2009 Munster PN, Marchion D, Thomas S, Egorin M, Minton S, Springett G, Lee JH, Simon G, Chiappori A, Sullivan D, Daud A
• Histone deacetylase inhibitor induced modulation of anti-estrogen therapy.
  Cancer letters 2009 Thomas S, Munster PN
• A Bir1p Sli15p kinetochore passenger complex regulates septin organization during anaphase.
  Molecular biology of the cell 2007 Thomas S, Kaplan KB
• A novel role for the CBF3 kinetochore-scaffold complex in regulating septin dynamics and cytokinesis.
  The Journal of cell biology 2005 Gillis AN, Thomas S, Hansen SD, Kaplan KB
• Sgt1p and Skp1p modulate the assembly and turnover of CBF3 complexes required for proper kinetochore function.
  Molecular biology of the cell 2004 Rodrigo-Brenni MC, Thomas S, Bouck DC, Kaplan KB
• Eukaryotic glycosyltransferases: cysteines and disulfides.
  Glycobiology 2002 Thomas S, Yen TY, Macher BA
• Human alpha 1,3/4 fucosyltransferases. Characterization of highly conserved cysteine residues and N-linked glycosylation sites.
  The Journal of biological chemistry 2000 Holmes EH, Yen TY, Thomas S, Joshi R, Nguyen A, Long T, Gallet F, Maftah A, Julien R, Macher BA
• A historically controlled trial of tyrosine for cocaine dependence.
  Journal of psychoactive drugs 1996 Galloway GP, Frederick SL, Thomas S, Hayner G, Staggers FE, Wiehl WO, Sajo E, Amodia D, Stewart P